Cadila Pharmaceuticals Limited

Overview

Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, committed to the development and commercialization of innovative therapeutic solutions. With a wide-ranging portfolio that spans numerous therapeutic areas, Cadila is dedicated to improving patient outcomes globally.

Core services & business areas

Therapeutic areas

Active pharmaceutical ingredients supplied

Substances Cadila Pharmaceuticals Limited is evidenced to supply (US FDA Drug Master File or EU CEP). Open any ingredient to see its full supplier landscape, CAS number and patent status.

API / Drug Master Files

Cadila Pharmaceuticals Limited holds 32 active (58 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• GEMFIBROZIL USPActive2020-07-10
• HYDRALAZINE HYDROCHLORIDE USPActive2020-07-03
• VENLAFAXINE HYDROCHLORIDE USP (PROCESS-2)Active2015-09-23
• ARIPIPRAZOLE USPActive2015-09-11
• BUPROPION HYDROCHLORIDE USPActive2014-12-31
• CARVEDILOL USPActive2014-04-18
• ATORVASTATIN CALCIUM USP FORM-IActive2014-04-16
• PHTHALOYL AMLODIPINEActive2014-01-31
• NATEGLINIDE FORM H USPActive2013-06-21
• RALOXIFENE HYDROCHLORIDE USPActive2013-05-06
• BOSENTAN MONOHYDRATEActive2013-03-05
• VALSARTAN USP (PROCESS 2)Active2012-07-07
• PALIPERIDONE USPActive2010-11-29
• OLMESARTAN MEDOXOMIL USPActive2009-08-26
• ATOMOXETINE HYDROCHLORIDE USPActive2009-08-11

Showing 15 of 58 Drug Master Files.

FDA compliance signals